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Abstract: This study was designed to evaluate the effects of strontium on the expression levels
of microRNAs (miRNAs) and to explore their effects on skeletal cell proliferation, differentiation,
adhesion, and apoptosis. The targets of these miRNAs were also studied. Molecular cloning, cell
proliferation assay, cell apoptosis assay, quantitative real-time PCR, and luciferase reporter assay were
used. Strontium altered the expression levels of miRNAs in vitro and in vivo. miR-9-5p, miR-675-5p,
and miR-138-5p impaired skeletal cell proliferation, cell differentiation and cell adhesion. miR-9-5p
and miR-675-5p induced MC3T3-E1 cell apoptosis more specifically than miR-138-5p. miR-9-5p,
miR-675-5p, and miR-138-5p targeted glycogen synthase kinase 3 β (GSK3β), ATPase Aminophospholipid
Transporter Class I Type 8A Member 2 (ATP8A2), and Eukaryotic Translation Initiation Factor 4E
Binding Protein 1 (EIF4EBP1), respectively. Low-density lipoprotein receptor-related protein 5 (LRP5)
played a positive role in skeletal development. miR-9-5p, miR-675-5p, and miR-138-5p damage
strontium and LRP5-mediated skeletal cell proliferation, differentiation, and adhesion, and induce
cell apoptosis by targeting GSK3β, ATP8A2, and EIF4EBP1, respectively.
Keywords: microRNA or miRNA; bone; strontium; cell proliferation; differentiation; adhesion and
apoptosis; target; LRP5
1. Introduction
Strontium ranelate is a drug used for treating osteoporosis. The effects of strontium result in
increased bone formation and decreased bone resorption [1]. Our previous studies showed that
strontium promoted osteogenic differentiation of mesenchymal stem cells [2]. However, the exact
mechanism of the effects of strontium ranelate remains unclear.
The miRNAs play vital roles in bone formation, so they may be used in the diagnosis and treatment
of many diseases such as osteoporosis. For instance, miR-138 inhibits the osteogenic differentiation
of mesenchymal stem cells [3]. miR-370 remarkably attenuates BMP-2-induced pre-osteoblast
differentiation [4]. miRNAs inhibit gene expression through binding to the 31-untranslated region
(31UTR) of target mRNAs. Multiple studies have demonstrated that miRNAs regulate most biological
processes of cells, including proliferation, differentiation, and apoptosis [5]. Severe diseases can be
attributed to abnormal expression of miRNA. Though there are many studies in the relationship
between the miRNAs and bone remodeling, the studies for the strontium regulating the miRNAs are
very few.
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We and other investigators found that the expression levels of β-cantenin increased significantly
after strontium treatment [6], and the Wnt signaling pathways were activated by strontium. Wnt
signaling pathways play important roles in bone formation. LRP5 is a co-receptor of the Wnt signaling
pathways. Our previous study indicated that strontium could increase the mRNA levels of LRP5 in
wild-type mice [6]. Sclerostin has anti-anabolic effects on skeletal development and inhibits osteoblast
differentiation and bone formation [7]. Sclerostin has been identified as binding to LRP5 and inhibiting
the Wnt signaling pathways [8]. The inhibition of the Wnt signaling pathways results in decreased
bone formation [9]. Transfection of a hairy/enhancer-of-split related with YRPW motif protein 1 (Hey1)
expression plasmid reversed the upregulation of differentiation markers in the MC3T3-E1 cells [10].
This revealed the importance of Hey1 as a potent negative regulator of osteogenesis in regulating
osteoblastic differentiation. The studies have showed that Hey1 negatively influences osteoblastic
differentiation and inhibition of Hey1 enhanced the osteoblastic differentiation. Mothers against
decapentaplegic homolog 6 (Smad6) acts as a negative regulator of bone morphogenetic proteins. It is
demonstrated that Mothers against decapentaplegic homolog 7 (Smad7), as well as Smad6, inhibits
proliferation and differentiation of osteoblastic cells [11].
In this study, we detected the expression levels of miRNAs affected by the strontium and explored
the roles of these miRNAs in skeletal development. In addition, we studied the potential targets of
three important miRNAs and the roles LRP5 played in bone formation.
2. Results
2.1. Strontium Altered the Expression Levels of miRNAs in Vitro and in Vivo
MC3T3-E1 cells (4 ˆ 105 cells/well) in the six-well plates were treated with strontium ranelate six
hours after seeding. We detected the miRNAs that were related to bone formation according to previous
studies [12–18]. Results showed the down-regulation of miR-9-5p upon strontium ranelate treatment
but there were no significant changes (Figure 1A). We also found the expression of miR-142-3p
decreased after the strontium treatment (Figure 1B). Additionally we detected other miRNAs including
miR-675-5p, miR-138-5p, miR-27b, miR-140, miR-141, and miR-103 but there were no changes in the
expression levels of these miRNAs (Figure S1).
Figure 1. Strontium altered the expression levels of miRNA in vitro and in vivo. (A) Expression levels
of miR-9-5p in MC3T3-E1 cells upon strontium ranelate treatment; (B) Expression levels of miR142-3p
in MC3T3-E1 cells upon strontium ranelate treatment; (C) Expression levels of ALP in the bone of the
mice upon strontium treatment; (D) Expression levels of miRNAs in the bone of mice upon strontium
treatment. ** p < 0.01.
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To further study the effects of strontium on expression levels of miRNAs in vivo, we treated the
mice with strontium ranelate. To verify the positive effects of strontium on bone formation of these
mice, we detected the alkaline phosphatase (ALP), a byproduct of osteoblast activity, and it increased
if there was bone formation occurring. Results showed that ALP increased significantly with the fold
change of 146.4 in the bone of the mice treated with strontium (Figure 1C), suggesting that strontium
promoted bone formation in vivo. Then, we detected the levels of miRNAs in the bone of mice. Results
showed that the expression levels of miR-675-5p, miR-138-5p, miR-370, miR-23a, and miR-103 were
significantly inhibited by strontium ranelate (Figure 1D).
2.2. miR-9-5p, miR-675-5p, and miR-138-5p Reduced Skeletal Cell Count and Cell Proliferation
Since our data showed strontium inhibited miR-9-5p and miR-142-3p in vitro, we further studied
previous reports of these two miRNAs. miR-9 dysregulation is implicated in a variety of human
diseases, but its role remains contradictory [19,20]. In addition, its roles in bone formation were
not well studied. We also further studies the five decreased miRNAs in vivo. miR-138-5p was the
most significantly inhibited miRNA among these five miRNAs, and there were few studies of the
influences of miR-675-5p on skeletal development. Thus, we further studied miR-9-5p, miR-675-5p,
and miR-138-5p.
First of all, we studied the influences on cell count of these three miRNAs. We seeded the same
numbers of MC3T3-E1 cells (5 ˆ 104 cells/well) in six-well plates. The cells were transfected with
miR-9-5p, miR-675-5p, and miR-138-5p mimics (40 nM). Every group contained triplicate wells. Photos
were taken four days after transfection. The numbers of cells treated with miR-9-5p, miR-675-5p, and
miR-138-5p mimics were apparently less than the control group (Figure 2A), indicating that miR-9-5p,
miR-675-5p, and miR-138-5p, especially miR-9-5p, reduced cell count.
To further investigate mechanisms underlying miR-dependent changes in cell count, we
conducted a series of cell proliferation assays. Firstly, clonogenic assay results revealed that clonogenic
survival were decreased following overexpression of miR-9-5p, miR-675-5p, and miR-138-5p in the
MC3T3-E1 cells (Figure 2B,C). Secondly, we tested the cell viability of MC3T3-E1 and ATDC5 cells
transfected with serial dilution of miRNAs by using resazurin measurement. With the increase of the
concentration of miR-9-5p, the fluorescence decreased (Figure 2D), indicating that miR-9-5p damaged
viability of these two kinds of cells. In addition, miR-675-5p decreased the MC3T3-E1 cell viability
while miR-138-5p decreased the ATDC5 cell viability (Figure 2D). Thirdly, WST-1-based colorimetric
assay showed that miR-9-5p had cell cytotoxicity and inhibited MC3T3-E1 cell proliferation in a
dose-dependent manner (Figure 2E). Fourthly, we detected the levels of proliferating cell nuclear
antigen (PCNA), an important proliferation marker. Results showed that miR-675-5p and miR-138-5p
significantly decreased PCNA in MC3T3-E1 cells (Figure 2F). We also found that miR-9-5p significantly
(p < 0.01) reduced the levels of Cyclin A, Cyclin D1, and Cyclin E in ATDC5 cells, and miR-675-5p
significantly (p < 0.01) reduced the Cyclin E in MC3T3-E1 and Cyclin D1 in ATDC5 cells (data
not shown).
Taken together, these data strongly suggested that miR-9-5p, miR-675-5p, and miR-138-5p reduced
skeletal cell proliferation.
Int. J. Mol. Sci. 2016, 17, 236 4 of 15
Figure 2. miR-9-5p, miR-675-5p, and miR-138-5p reduced skeletal cell count and cell proliferation.
(A) Representative photos of MC3T3-E1 cells transfected with miR-9-5p, miR-675-5p, and miR-138-5p;
(B) Representative pictures of clonogenic assay with miR-9-5p, miR-675-5p, and miR-138-5p;
(C) The clonogenic potential of MC3T3-E1 transfected with miR-9-5p, miR-675-5p, and miR-138-5p;
(D) Fluorescence changes of MC3T3-E1 transfected with miR-9-5p and miR-675-5p, and ATDC5
transfected with miR-9-5p and miR-138-5p; (E) Determination of the cytotoxic activity of miR-9-5p on
MC3T3-E1 cells; (F) Expression levels of PCNA in MC3T3-E1 cells upon transfection of miR-675-5p
and miR-138-5p ** p < 0.01. n = 3/group.
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2.3. miR-9-5p, miR-675-5p, and miR-138-5p Impaired Skeletal Cell Differentiation and Cell Adhesion
We further studied the roles of these three miRNAs played in the expression levels of LRP5 and
Runt-related transcription factor 2 (RUNX2). RUNX2 is a key transcription factor associated with
osteoblast differentiation. Results showed all these three miRNAs inhibited the expression levels
of LRP5 and RUNX2 (Figure 3A,B). In addition, miR-9-5p inhibited the LRP5 and RUNX2 more
significantly than the other two miRNAs. To further confirm these results, we used another cell line
ATDC5, a model for skeletal development. Results were similar with that of MC3TC-E1cells (data not
shown). More specifically, miR-9-5p, miR-675-5p, and miR-138-5p inhibited the expression of RUNX2
in ATDC5 cells. In addition, miR-9-5p significantly (p < 0.01) inhibited the levels of RUNX2 in ATDC5
cells (data not shown). Since all these data suggested that miR-9-5p more adversely impaired the
skeletal development, we detected another biomarker Collagen, type I, α 1 (COL1A1), a protein that
strengthens and supports bone. Results showed that miR-9-5p significantly inhibited the levels of
COL1A1 in both MC3TC-E1 and ATDC5 cells (Figure 3C).
We examined total 15 cell adhesion markers including four integrins (Integrin α2, Integrin α5,
Integrin αV, and Integrin β1), one extracellular matrix component (Fibronectin), 2 focal adhesion
markers (FAK and Vinculin), three osteoblast specific markers (Osteocalcin, Osteonectin and
Osteopontin), two collagens (Type I collagen and Type III collagen), Cadherin 11, Mitogen Activated
Protein Kinase (MAPK), and Nuclear Factor κB (NFκB) according to previous studies [21]. The results
of these three miRNAs regulating the 15 cell adhesion markers in MC3T3-E1 cells were listed in the
Figure 3D and Table S1. miR-9-5p, miR-675-5p, and miR-138-5p generally decreased these 15 cell
adhesion markers with a few exceptions (Figure 3D), suggesting that these three miRNAs decreased
skeletal cell adhesion.
Taken together, these data strongly suggested that miR-9-5p, miR-675-5p, and miR-138-5p,
impaired the skeletal cell differentiation and cell adhesion.
Figure 3. miR-9-5p, miR-675-5p, and miR-138-5p impaired skeletal cell differentiation and cell adhesion.
(A) Expression levels of LRP5 in MC3T3-E1 cells upon transfection of miR-9-5p, miR-675-5p, and
miR-138-5p; (B) Expression levels of RUNX2 in MC3T3-E1 cells upon transfection of miR-9-5p,
miR-675-5p, and miR-138-5p, respectively; (C) Expression levels of COL1A1 upon transfection of
miR-9-5p (5 nM); (D) Expression levels of 15 cell adhesion markers in MC3T3-E1 cells upon transfection
of miR-9-5p, miR-675-5p, and miR-138-5p. * p < 0.05. ** p < 0.01. n = 3/group.
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2.4. miR-9-5p and miR-675-5p Induced MC3T3-E1 Cell Apoptosis More Specifically than miR-138-5p
miR-9-5p significantly increased the levels of pro-apoptotic regulator Fas ligand (FasL) with
fold change of 28.3 and miR-675-5p increased the levels of FasL with fold change of 35.3, while
miR-138-5p slightly increased the levels of FasL (Figure 4A). We also detected another classical
pro-apoptotic regulator p53, and the results were similar. miR-9-5p induced MC3T3-E1 cell apoptosis
more specifically than miR-138-5p (Figure 4B). TUNEL cell apoptosis assay showed that miR-9-5p and
miR-675-5p induced cell apoptosis while miR-138-5p slightly induced apoptosis (Figure 4C). In other
words, cell apoptosis seen by miR-9-5p and miR-675-5p overexpression were more specific than that of
miR-138-5p.
Figure 4. miR-9-5p and miR-675-5p induced MC3T3-E1 cell apoptosis more specifically than
miR-138-5p. (A) Expression levels of FasL in MC3T3-E1 cells upon transfection of miR-9-5p, miR-675-5p,
and miR-138-5p; (B) Expression levels of p53 in MC3T3-E1 cells upon transfection of miR-9-5p,
miR-675-5p, and miR-138-5p, respectively; (C) TUNEL cell apoptosis assay of miR-9-5p, miR-675-5p,
and miR-138-5p. * p < 0.05. n = 2/group.
2.5. miR-9-5p, miR-675-5p, and miR-138-5p Targeted GSK3β, ATP8A2, and EIF4EBP1
To further study the downstream targets of these miRNAs, we used the miRNA target prediction
software to seek for the potential targets. The genes GSK3β, ATP8A2, and EIF4EBP1 were predicted to
be the targets of miR-9-5p, miR-675-5p, and miR-138-5p, respectively. Figure 5A showed the predicted
miR-9-5p, miR-675-5p, and miR-138-5p targeting sequence located in the 3’UTR of GSK3β, ATP8A2,
and EIF4EBP1, respectively.
Then we assessed whether overexpression of miR-9-5p, miR-675-5p, and miR-138-5p suppressed
the expression of GSK3β, ATP8A2, and EIF4EBP1. Forced expression of miR-9-5p, miR-675-5p, and
miR-138-5p inhibited the mRNA level of GSK3β, ATP8A2, and EIF4EBP1, respectively, in the MC3T3-E1
cell (Figure 5B). There were concordant results in another cell line, ATDC5 (data not shown).
To confirm the regulation of GSK3β, ATP8A2, and EIF4EBP1 by miR-9-5p, miR-675-5p, and
miR-138-5p, we cloned and inserted the wild-type and mutant fragments of the 3’UTR of these three
genes containing the binding sites of miR-9-5p, miR-675-5p, and miR-138-5p into the luciferase vector.
Luciferase–3’UTR plasmids were co-transfected into MC3T3-E1 cells with or without miRNA mimics,
followed by Dual-Light luminescent reporter gene assay. Transfection of miR-9-5p, miR-675-5p and
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miR-138-5p mimics resulted in a reduction in luciferase activity in MC3T3-E1 cells transfected with wild
type Luciferase–3’UTR plasmids (Figure 5C), while the inhibition of luciferase activity by these three
miRNAs was abrogated in MC3T3-E1 cells transfected with mutant plasmids. miR-9-5p, miR-675-5p,
and miR-138-5p inhibited their wild-type targets more significantly than mutant ones (Figure 5C), so
resistance of mutant luciferase vectors to miRNAs confirmed the specific targeting.
Taken together, these results strongly suggested that miR-9-5p, miR-675-5p, and miR-138-5p
decreased GSK3β, ATP8A2, and EIF4EBP1 by directly binding to their 3’UTR.
Figure 5. miR-9-5p, miR-675-5p and miR-138-5p targeted GSK3β, ATP8A2, and EIF4EBP1, respectively.
(A) The predicted miR-9-5p, miR-675-5p, and miR-138-5p targeting sequence located in the 3’UTR of
GSK3β, ATP8A2, and EIF4EBP1; (B) The mRNA level of GSK3β, ATP8A2, and EIF4EBP1 in MC3T3-E1
cells transfected with miR-9-5p, miR-675-5p, and miR-138-5p mimics; (C) The relative luciferase
activity of MC3T3-E1 cells transfected with miR-9-5p, miR-675-5p, and miR-138-5p mimics (20 nM for
miR-675-5p and miR-138-5p, and 10 nM for miR-9-5p). * p < 0.05. ** p < 0.01. n = 3/group.
2.6. LRP5 Played Positive Roles in Skeletal Development
Since our data showed that the miR-9-5p suppressed the GSK3β, a component of the Wnt signaling
pathways. We further studied their upstream regulator LRP5, an important co-receptor in the Wnt
pathways. We seeded the same numbers of MC3T3-E1 cells (500 cells/well) in six-well plates. The cells
were transfected with a serial of silence RNA siLRP5 (15, 30, or 60 nM) to silence the function of LRP5.
Every group contained triplicate wells. Photos were taken five days after transfection. From Figure 6A
we can see that the numbers of cells decreased in a dose-dependent manner, indicating that LRP5
were essential for cell proliferation. To further verify this point, we stained the cells with crystal violet.
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The results revealed that clonogenic survival were decreased in a dose-dependent manner following
silence of LRP5 in the MC3T3-E1 cells (Figure 6B,C).
To further study the whether LRP5 played positive roles in skeletal development, we detected the
levels of RUNX2 in MC3T3-E1 cells transfected with siLRP5 (5 nM). Results showed that the mRNA
expression of RUNX2 decreased after the function of LRP5 was blocked by siLRP5 (Figure 6D). To
confirm the positive effects of LRP5, we checked if LRP5 knockdown induced increased expression of
negative regulators of skeletal development. According to previous studies [7–11], we detected four
negative regulators, namely sclerostin, Hey1, Smad6, and Smad7. Results showed that all four negative
regulators increased after the MC3T3-E1 cells were treated with siLRP5 (Figure 6E). Specifically, silence
of LRP5 led to significantly increased sclerostin with fold change value of 8.5. These four increased
negative factors, together with decreased LRP5, adversely accelerated the damage of bone formation.
Taken together, these results strongly suggested that LRP5 were essential for skeletal development.
Figure 6. LRP5 played positive roles in the skeletal development. (A) Representative photos of
MC3T3-E1 cells transfected with siLRP5; (B) Representative pictures of colonies of MC3T3-E1 cells
transfected with siLRP5; (C) The clonogenic potential of MC3T3-E1 cells transfected with siLRP5;
(D) Expression levels of RUNX2 in MC3T3-E1 cells upon siLRP5 treatment; (E) Fold changes of
sclerostin, Hey1, Smad6, and Smad7 in MC3T3-E1 cells upon siLRP5 treatment. * p < 0.05, ** p < 0.01.
n = 3/group.
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3. Discussion
In conclusion, our results showed strontium decreased the expression levels of miR-9-5p,
miR-675-5p, and miR-138-5p, and these three miRNAs inhibited the levels of LRP5 and RUNX2.
These results indicate that strontium may activate the Wnt signaling pathways including LRP5 and
then increase the levels of RUNX2 leading to osteoblast proliferation and differentiation by inhibiting
these three miRNAs. In the current study we have revealed that GSK3β, ATP8A2, and EIF4EBP1 are the
target genes of miR-9-5p, miR-675-5p, and miR-138-5p through three aspects. Firstly, target prediction
tools have shown the exact binding sites between the miRNAs and the 3’UTR of the genes. Secondly,
the downregulation of the target genes upon treatment of miRNAs indicates that the miRNAs have
bound to the 3’UTR of the genes and degraded their target genes. Thirdly, the decrease of luciferase
activity verified this point. The relationships found or verified in this study are summarized in the
flowchart (Figure 7).
Figure 7. The flowchart of the main study objects and their relationships.
Our results showed that the expression levels of miR-370, miR-378, and miR-320 were inhibited by
strontium. The enforced expression of miR-370 in MC3T3-E1 cells or stable transfection of MC3T3-E1
cells with miR-378 attenuated pre-osteoblast differentiation [4,22], indicating that strontium might
promote cell differentiation by inhibiting the expression of miR-370 and miR-378. Concordant with
our results, stable expression of miR-320 suppressed osteogenic differentiation [23].
Clonogenic assay showed that miR-9-5p inhibited the cell proliferation more significantly than
the other two miRNAs and qPCR revealed miR-9-5p suppressed the expression levels of LRP5 and
RUNX2 more significantly than the other two miRNAs, so these two methods generated concordant
results, that is to say, miR-9-5p more adversely impaired the cell proliferation and differentiation.
Our results showed that miR-138-5p impaired skeletal development. Martin et al. [15] reported that
miR-138-5p had anti-osteoblastic effects, supporting our results.
In the clonogenic assay we used final concentration 5 nM miR-9-5p, 10 nM miR-675-5p, and
10 nM miR-138-5p. The concentration of miRNAs may influence the colony formation rate of the cells.
Excessively high concentration of miRNAs may slow the cell proliferation. Our results have shown
that 5 nM miR-9-5p almost killed all the cells. In fact, we also used 20 nM miR-9-5p and the results
were similar with that of 5 nM, indicating that 5 nM miR-9-5p is enough to inhibit cell proliferation
and kill the cells. Recent studies reported that miR-9 could mediate the cell apoptosis in ischemic
stroke [24].
Wnt signaling pathways played important roles in osteoblast differentiation and bone
formation [25]. Since LRP5 was a critical co-receptor of Wnt signaling pathways, its loss of function
may limit the osteoblast cell proliferation and differentiation, which was supported by our data.
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miR-9 restoration retarded HCC cell proliferation and migration. Since our results have shown that
miR-9 inhibits MC3T3-E1 cell proliferation, these results indicate that miR-9 inhibits cell proliferation
not only in bone cells, but also in cancer cells, thus providing potential therapeutic targets and novel
prognostic biomarkers. miR-675 was upregulated in livers with HBV infection and was associated
with immune response pathways [26], indicating that viruses and drugs affect the cells and the bodies
through altering the levels of miRNAs such as miR-675. Further studies of these miRNAs are needed
to reveal the mechanisms of drugs and disease progression.
4. Experimental Section
4.1. Cell Cultures and Reagents
MC3T3-E1 cells were cultured in Alpha MEM medium (Gibco, Hong Kong, China) supplemented
with 10% FBS (Gibco, Hong Kong, China), penicillin, streptomycin sulfate, and fungizone.
ATDC5 cells were cultured in DMEM/F12 supplemented with 10% FBS, penicillin, streptomycin
sulfate, and fungizone. Strontium ranelate was purchased from Servier (Orléans, France).
The sequences of miRNA mimics (Qiagen, Duesseldorf, Germany) were as follows: miR-9-5p:
51-UCUUUGGUUAUCUAGCUGUAUGA-31; miR-675-5p: 51-UGGUGCGGAAAGGGCCCACAGU-31;
miR-138-5p: 51-AGCUGGUGUUGUGAAUCAGGCCG-31.
4.2. Plasmid Construction
To generate the 3’UTR of GSK3β containing the binding sites of miR-9-5p ligating luciferase
plasmid, we extracted RNA from the cells and then converted the RNA into cDNA. Using
the cDNA as the template, we amplified the fragment containing the binding sites of the
miR-9-5p by using Platinum® Pfx DNA Polymerase (Invitrogen, Hong Kong, China). We used
the software CLC Genomics Workbench to design primers, which were as follows: Forward
5’-CGAGCTCTGTGTGTGTGTGTGTGTG-3’; Reverse: 5’-TTCCGCGGCCGCTATGGCCGACGTCGA
CGGGAATGGGGAAAGGGAA-3’. After confirmation of electrophoresis, the PCR products were
purified, digested with SacI and SalI, purified, ligated with the vector pmirGLO Dual-Luciferase
miRNA Target Expression Vector (Promega Corporation, Madison, WI, USA), followed by the
transformation by heat shock, analyzing the transformants by colony PCR, electrophoresis, sequencing,
and plasmid extraction.
The 31UTR of ATP8A2 and EIF4EBP1 containing the binding sites of miR-675-5p and miR-138-5p
were synthesized. The sequences for 31UTR of ATP8A2 and EIF4EBP1 were as follows: ATP8A2:
51-CCCUGGAAGAGUCUUCCGCACCC-31; EIF4EBP1: 51-CCUCCUCUUCGUGAACACCAGCA-31.
We dissolve the oligonucleotides in water to 20 µM and set up total 20 µL reactions as follows: 1 µL
forward oligo, 1 µL reverse oligo and 18 µL 10 mM Tris-HCl, pH 8.5 or 8.0. The mixture was heated to
95 ˝C for 2 min and then cooled to room temperature. The inserts 31UTR of ATP8A2 and EIF4EBP1
were cloned into pMIR-REPORT Luciferase vector (Applied Biosystems, Hong Kong, China).
4.3. Transfection
For miRNA transfection and siLRP5 transfection, we added 0.5% HiPerfect Transfection Reagent
(Qiagen) into serum-free medium. The mixture of medium without serum and miRNAs was incubated
for 10 min at room temperature before adding them into cells. For plasmid transfection, MC3T3-E1
cells were seeded in 96 well plates. Cells were co-transfected with 60 ng/well of plasmids and miRNA
mimics by using Lipofectamine 2000 (Invitrogen). For siRNA, RNA extraction from the cells was
conducted at 48 h after the transfection. For miRNAs, RNA extraction was conducted at 72 or 48 h
after transfection.
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4.4. Clonogenic Assay (Colony Formation Assay)
Clonogenic assay was conducted according to the published protocol [27]. In brief, MC3T3-E1
cells were seeded with the density of 500 cells/well of the six-well plate. miR-9-5p, miR-675-5p, and
miR-138-5p were transfected and their concentrations were maintained by adding these miRNAs
three days after the first transfection. One week after the first transfection, the cells were fixed by 70%
ethanol and stained by 0.5% crystal violet (Sigma, St. Louis, MO, USA). Clones were considered to
represent viable cells if they contained in excess of 50 cells.
4.5. Cell Viability Assay
Cell viability assay was conducted by using CellTiter-Blue® Cell Viability Assay (Promega
Corporation) using resazurin. In brief, the MC3T3-E1 and ATDC5 cells were seeded with a
concentration of 100 cells/150 µL and transfected with a serial dilution of miRNAs (500, 250, 125, 62.5,
and 31.25 nM). The concentration were maintained by a second transfection three days after the first
transfection. Six days after the first transfection, the cells were added with CellTiter-Blue® Reagent
and the fluorescence was measured.
4.6. Cell Cytotoxicity Assay
We test the cell cytotoxicity of miR-9-5p by using colorimetric assay (WST-1 based). In brief,
MC3T3-E1 cells were seeded with the concentration of 5000 cells/well in the 96-well plate and
transfected with a serial dilution of miR-9-5p (0, 200, 400, and 800 nM). The assay were conducted
after two days. The wavelength for measuring the absorbance of the formazan product was 440 nm
and reference wavelength was 690 nm. The blank background control was made by adding the same
volume of culture medium and WST-1 into one well.
4.7. TUNEL Cell Apoptosis Assay
We conducted cell apoptosis assay by using ApopTag® Red In Situ Apoptosis Detection Kit (Merck
Millipore Corporation, Darmstadt, Germany), which detected apoptosis by indirect TUNEL method,
utilizing an anti-digoxigenin antibody with a rhodamine fluorochrome. In brief, the MC3T3-E1 were
seeded into the chamber slides (8000 cells/150 µL/well) and transfected with three miRNAs (500 nM).
After two days, the assay was conducted according to manufacturer’s standard manual. The cells
were fixed in 1% paraformaldehyde in PBS and post-fixed in ethanol: acetic acid (2:1), sequentially
applied with Equilibration Buffer, TdT Enzyme, Stop/Wash Buffer, Anti-Digoxigenin Conjugate and
Rhodamine/DAPI Staining. When taking photos, we assured consistent parameters including scale,
exposure time and analog gain of the fluorescence microscopy for each picture so that all the pictures
were comparable.
4.8. Animal
All procedures were approved by the Committee on the Use of Live Animals in Teaching and
Research of The University of Hong Kong. Animal licenses were approved by the Department of Health
of the Government of Hong Kong. Mice with a B6.129P2 background were imported from Jackson
Laboratory (Bar Harbor, ME, USA). The heterozygous mice were crossed to obtain LRP5 knockout
mice. For genotypes analysis of the mice, DNA extraction were conducted by using the ears of the
mice, followed by PCR and agarose gel electrophoresis. The three primers used in the PCR were as
follows: 51-CACTGCATGGATGCCAGTGAGGTGG-31; 51-GCTGCCACTCATGGAGCCTTTATGC-31;
51-CGCTACCGGTGGATGTGGAATGTGT-31. We treated the mice with strontium ranelate daily by
oral gavage. The strontium ranelate was dissolved in water and made into suspension. The dosage
was 33.3 ng drug powder per gram (body weight).
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4.9. RNA Extraction
Total RNA from the cells or the bone of the mice was extracted by using TRIzol. The femur, tibia,
and fibula were cleaned of soft tissue and used for RNA extraction. For every well of six-well plate,
we used 1 mL TRIzol for RNA extraction from the cells. For RNA extraction from the bone, we used 1
mL TRIzol for approximately 200 mg fresh bone.
4.10. Poly (A) Polymerase Tailing
For expression of miRNAs detection, the RNA was polyadenylated by Poly (A) Polymerase
Tailing Kit (Epicentre® Biotechnologies) before reverse transcription.
4.11. Reverse Transcription
The RNA was mixed with random primer and reverse transcription was performed by
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Diluted
cDNA was used for PCR. For expression of miRNAs detection, the polyadenylated RNA was
mixed with reverse transcription primer (sequence: 51-GCGAGCACAGAATTAATACGACTCAC
TATAGGTTTTTTTTTTAG-31) instead of random primer.
4.12. Quantitative Real-Time PCR (qPCR)
qPCR was performed using the SYBR Green PCR Master Mix (Life Technologies Limited, Hong
Kong, China) on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Primers for qPCR were
purchased from the Integrated DNA Technologies. miRNA detection was conducted according to the
published paper [28]. In brief, the reaction was incubated at 95 ˝C for 10 min, followed by 45 cycles of
95 ˝C for 10 s and 60 ˝C for 1 min. For melting curve analysis the reactions were heated to 95 ˝C for 5 s
and 60 ˝C for 15 s, then cooled to 40 ˝C. For gene detection, the reaction was incubated at 95 ˝C for
10 min followed by 40 cycles of 95 ˝C for 15 s and 60 ˝C for 1 min. Reverse primer for all the miRNAs
were called RACE. The sequences for RACE, all the forward primers of miRNAs, and all the primers
of genes were listed in Table 1.
Table 1. Sequences of all primers.
Primer Name Sequences (5’–3’)
RACE Reverse GCGAGCACAGAATTAATACGAC
miR-9-5p Forward GCGTCTTTGGTTATCTAGCTGTA
miR-675-5p Forward TGGTGCGGAAAGGGCCCACAGT
miR-138-5p Forward AGCTGGTGTTGTGAATCAGGCCG
miR-370 Forward GCCTGCTGGGGTGGAACCTGGT
miR-23a Forward ATCACATTGCCAGGGATTTCC
miR-103 Forward ACACTCCAGCTGGGAGCAGCATTGTAC
GAPDH Forward ATTGTCAGCAATGCATCCTG
GAPDH Reverse ATGGACTGTGGTCATGAGCC
ALP Forward AACCCAGACACAAGCATTCC
ALP Reverse GCCTTTGAGGTTTTTGGTCA
COL1A1 Forward GCCAAGAAGACATCCCTGAA
COL1A1 Reverse GCCATTGTGGCAGATACAGA
RUNX2 Forward AAGTGCGGTGCAAACTTTCT
RUNX2 Reverse ACGCCATAGTCCCTCCTTTT
GSK3β Forward TTGGACAAAGGTCTTCCGGC
GSK3β Reverse AAGAGTGCAGGTGTGTCTCG
ATP8A2 Forward ACGAGGGACGTGCTCATGAAGC
ATP8A2 Reverse CCTCAAGTGTCACCAGCAGGCT
EIF4EBP1 Forward CTAGCCCTACCAGCGATGAG
EIF4EBP1 Reverse CCTGGTATGAGGCCTGAATG
LRP5 Forward TGCCACTGGTGAGATTGAC
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Table 1. Cont.
Primer Name Sequences (5’–3’)
LRP5 Reverse ACTGCTGCTTGATGAGGAC
Cyclin-D1 Forward GCGTACCCTGACACCAATCT
Cyclin-D1 Reverse CTCCTCTTCGCACTTCTGCT
CyclinA Forward CAGAGGCCGAAGACGAGAC
CyclinA Reverse TCAGCTGGCTTCTTCTGAGC
CyclinE Forward GTTATAAGGGAGACGGGGAG
CyclinE Reverse TGCTCTGCTTCTTACCGCTC
PCNA Forward TTTGAGGCACGCCTGATCC
PCNA Reverse GGAGACGTGAGACGAGTCCAT
Integrin α2 Forward AAGTGCCCTGTGGACCTACCCA
Integrin α2 Reverse TGGTGAGGGTCAATCCCAGGCT
Integrin α5 Forward ACCACCTGCAGAAACGAGAGGC
Integrin α5 Reverse TGGCCCAAACTCACAGCGCA
Integrin Av Forward TCCCACCGCAGGCTGACTTCAT
Integrin Av Reverse TCGGGTTTCCAAGGTCGCACAC
Integrin β1 Forward TTCAGACTTCCGCATTGGCT
Integrin β1 Reverse AATGGGCTGGTGCAGTTTTG
Fibronectin Forward TGCAGTGGCTGAAGTCGCAAGG
Fibronectin Reverse GGGCTCCCCGTTTGAATTGCCA
FAK Forward AGCACCTGGCCACCTAAGCAAC
FAK Reverse CATTGGACCGGTCAAGGTTGGCA
Vinculin Forward TCAAGCTGTTGGCAGTAGCCGC
Vinculin Reverse TCTCTGCTGTGGCTCCAAGCCT
Osteocalcin Forward AGCAGGAGGGCAATAAGGTAGT
Osteocalcin Reverse TCGTCACAAGCAGGGTTAAGC
Osteonectin Forward ATGTCCTGGTCACCTTGTACGA
Osteonectin Reverse TCCAGGCGCTTCTCATTCTCAT
Osteopontin Forward TGATTCTGGCAGCTCAGAGGA
Osteopontin Reverse CATTCTGTGGCGCAAGGAGATT
Type I collagen Forward CTCCTGACGCATGGCCAAGAA
Type I collagen Reverse TCAAGCATACCTCGGGTTTCCA
Type III collagen Forward CCCTGGCTCAAATGGCTCACCA
Type III collagen Reverse CCTTTCCACCAGGACTGCCGTT
Cadherin 11 Forward GGCCCAAACAGGTATCATCA
Cadherin 11 Reverse TTGGTTGTCCCTGAGAGTCC
MAPK1 Forward ATCCGGGCACCAACCATTGAGC
MAPK1 Reverse GTGGTCATTGCTGAGGTGCTGTGT
NFkB Forward AACCCATCGCCTTGGCATCCAC
NFkB Reverse AGTCGAAAAGGGCGTTGGCGT
FasL Forward GAGAATTGCTGAAGACATGACAATCC
FasL Reverse ATGGCTGGAACTGAGGTAGTTTTCAC
p53 Forward TAACAGTTCCTGCATGGGCGGC
p53 Reverse CGGAGGCCCATCCTCACCATCATCA
HEY1 Forward GCATACGGCAGGAGGGAAA
HEY1 Reverse CTGGGAAGCGTAGTTGTTGAGAT
Sost Forward GGAATGATGCCACAGAGGTCAT
Sost Reverse CCCGGTTCATGGTCTGGTT
Smad7 Forward GGACGCTGTTGGTACACAAG
Smad7 Reverse GCTGCATAAACTCGTGGTCATTG
SMAD6 Forward GCTCTAGGAATGCAGACGCTG
SMAD6 Reverse CAACAGGCAGTCAGCACAGTC
4.13. Luciferase Reporter Assay
Firefly luciferase activities were measured 48 h after transfection by using dual-light luminescent
reporter gene assay kit (Applied Biosystems) according to the standard protocol. In brief, cell lysate
was mixed with reagents for the luciferase reaction, the luciferase signal was measured by using a
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VICTOR™ X3 Multilabel Plate Reader (PerkinElmer, Waltham, MA, USA). After 40 min incubation,
β-galactosidase signal was initiated by addition of Accelerator-II and detected.
4.14. Statistical Analysis
Statistical analysis was performed using a t-test, and p < 0.05 was considered
statistically significant.
5. Conclusions
miR-9-5p, miR-675-5p, and miR-138-5p damage strontium and LRP5-mediated skeletal cell
proliferation, differentiation, and adhesion, and induce cell apoptosis by targeting GSK3β, ATP8A2,
and EIF4EBP1, respectively.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/
17/2/236/s1.
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